Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma

BACKGROUND: Surgery is the primary treatment for basal cell carcinoma (BCC). In locally advanced basal cell carcinoma (laBCC), surgery may cause functional or aesthetic damage. In laBCC, neoadjuvant administration of vismodegib, an inhibitor of the Hedgehog signaling pathway, may reduce tumor size,...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertrand, Nicolas, Guerreschi, Pierre, Basset-Seguin, Nicole, Saiag, Philippe, Dupuy, Alain, Dalac-Rat, Sophie, Dziwniel, Véronique, Depoortère, César, Duhamel, Alain, Mortier, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093898/
https://www.ncbi.nlm.nih.gov/pubmed/33997740
http://dx.doi.org/10.1016/j.eclinm.2021.100844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093898/
https://www.ncbi.nlm.nih.gov/pubmed/33997740
http://dx.doi.org/10.1016/j.eclinm.2021.100844

Ejemplares similares